RE:RE:RE:Just for fun...a $500 million USD offerInteresting discussion. I agree that a $500MM offer would never fly. Management has publicly stated they think the current EV of RVX is 1.7B USD and further that the pharmas they speak with agree with this. For me the best guide to what the company is and will be worth at points in time is the EV chart that has been towards the end of most of the last few presentations. The values on the chart have been well researched and can be supported by mgmt if you talk to them.
IMO however $500MM USD upfront money might be a starting point for CVR deal discussions. Ph3 cardiovascular and Ph2/3 CKD as well as apparently 6 or 7 other "ready to go" molecules has got to be increasingly attractive to some pharma looking to get a leg up in the epigenetics space. The fact that RVX now represents multiple opportunities would also lessen the risk to a purchaser. Personally I would very much like to see a CVR get done as it would de-risk the investment and the IP would land in hands that could afford to go to the clinic quickly with multiple new molecules. Quicker time to trials and hopefully to market could result in a very nice royalty stream to investors and any royalty stream that will eventually come down the pipe will likely come much quicker from a pharma rather than RVX which does not have the funding to do multiple trials in a time efficient manner.
One additional point. Some on here have suggested that a purchaser would make an offer but then RVX would have to pay off the LoC from the proceeds. Generally offers to purchase include assumption of debt and don't forget that now, on a cash basis, the value of RVX tax credits is probably worth more to a profitable US company than the negative value of the debt.
All JMO